Literature DB >> 21612213

The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder.

J Nicole Burns1, Katherine C Turnage, Chandler A Walker, Raquel L Lieberman.   

Abstract

Myocilin variants, localized to the olfactomedin (OLF) domain, are linked to early-onset, inherited forms of open-angle glaucoma. Disease-causing myocilin variants accumulate within trabecular meshwork cells instead of being secreted to the trabecular extracellular matrix of the eye. We hypothesize that, like in other diseases of protein misfolding, aggregation and downstream pathogenesis originate from the compromised thermal stability of mutant myocilins. In an expansion of our pilot study of four mutants, we compare 21 additional purified OLF variants by using a fluorescence stability assay and investigate the secondary structure of the most stable variants by circular dichroism. Variants with lower melting temperatures are correlated with earlier glaucoma diagnoses. The chemical chaperone trimethylamine N-oxide is capable of restoring the stability of most, but not all, variants to wild-type (WT) levels. Interestingly, three reported OLF disease variants, A427T, G246R, and A445V, exhibited properties indistinguishable from those of WT OLF, but an increased apparent aggregation propensity in vitro relative to that of WT OLF suggests that biophysical factors other than thermal stability, such as kinetics and unfolding pathways, may also be involved in myocilin glaucoma pathogenesis. Similarly, no changes from WT OLF stability and secondary structure were detected for three annotated single-nucleotide polymorphism variants. Our work provides the first quantitative demonstration of compromised stability among many identified OLF variants and places myocilin glaucoma in the context of other diseases of protein misfolding.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21612213      PMCID: PMC3128542          DOI: 10.1021/bi200231x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  70 in total

Review 1.  Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth.

Authors:  Ming Liu; Israel Hodish; Leena Haataja; Roberto Lara-Lemus; Gautam Rajpal; Jordan Wright; Peter Arvan
Journal:  Trends Endocrinol Metab       Date:  2010-08-18       Impact factor: 12.015

2.  In vitro and in vivo study on the secretion of the Gly367Arg mutant myocilin protein.

Authors:  Janakaraj Kanagavalli; P J Eswari Pandaranayaka; Subbaiah Ramasamy Krishnadas; Sankaran Krishnaswamy; Periasamy Sundaresan
Journal:  Mol Vis       Date:  2007-07-13       Impact factor: 2.367

3.  The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.

Authors:  Richard A Steet; Stephen Chung; Brandon Wustman; Allan Powe; Hung Do; Stuart A Kornfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

4.  Founder effect in GLC1A-linked familial open-angle glaucoma in Northern France.

Authors:  A P Brézin; M F Adam; A Belmouden; M A Lureau; A Chaventré; B Copin; L Gomez; S D De Dinechin; M Berkani; F Valtot; J F Rouland; J C Dascotte; J F Bach; H J Garchon
Journal:  Am J Med Genet       Date:  1998-04-13

5.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.

Authors:  A N Bullock; J Henckel; A R Fersht
Journal:  Oncogene       Date:  2000-03-02       Impact factor: 9.867

6.  Rescue of glaucoma-causing mutant myocilin thermal stability by chemical chaperones.

Authors:  J Nicole Burns; Susan D Orwig; Julia L Harris; J Derrick Watkins; Douglas Vollrath; Raquel L Lieberman
Journal:  ACS Chem Biol       Date:  2010-05-21       Impact factor: 5.100

7.  Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis.

Authors:  Gary Hin-Fai Yam; Katarina Gaplovska-Kysela; Christian Zuber; Jürgen Roth
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-04       Impact factor: 4.799

Review 8.  Proinsulin and the genetics of diabetes mellitus.

Authors:  Michael A Weiss
Journal:  J Biol Chem       Date:  2009-04-24       Impact factor: 5.157

9.  Founder TIGR/myocilin mutations for glaucoma in the Québec population.

Authors:  Mathieu Faucher; Jean-Louis Anctil; Marc-André Rodrigue; Annie Duchesne; Dan Bergeron; Pierre Blondeau; Gilles Côté; Stéphane Dubois; Josée Bergeron; Rose Arseneault; Jean Morissette; Vincent Raymond
Journal:  Hum Mol Genet       Date:  2002-09-01       Impact factor: 6.150

10.  Pro370Leu mutant myocilin disturbs the endoplasm reticulum stress response and mitochondrial membrane potential in human trabecular meshwork cells.

Authors:  Lina Wang; Yehong Zhuo; Bingqian Liu; Shengsong Huang; Fei Hou; Jian Ge
Journal:  Mol Vis       Date:  2007-04-19       Impact factor: 2.367

View more
  30 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

2.  Differential Misfolding Properties of Glaucoma-Associated Olfactomedin Domains from Humans and Mice.

Authors:  Athéna C Patterson-Orazem; Shannon E Hill; Yiming Wang; Iramofu M Dominic; Carol K Hall; Raquel L Lieberman
Journal:  Biochemistry       Date:  2019-03-12       Impact factor: 3.162

3.  Trifunctional High-Throughput Screen Identifies Promising Scaffold To Inhibit Grp94 and Treat Myocilin-Associated Glaucoma.

Authors:  Dustin J E Huard; Vincent M Crowley; Yuhong Du; Ricardo A Cordova; Zheying Sun; Moya O Tomlin; Chad A Dickey; John Koren; Laura Blair; Haian Fu; Brian S J Blagg; Raquel L Lieberman
Journal:  ACS Chem Biol       Date:  2018-02-20       Impact factor: 5.100

4.  Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma.

Authors:  Andrew R Stothert; Amirthaa Suntharalingam; Dustin J E Huard; Sarah N Fontaine; Vincent M Crowley; Sanket Mishra; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

5.  Stable calcium-free myocilin olfactomedin domain variants reveal challenges in differentiating between benign and glaucoma-causing mutations.

Authors:  Shannon E Hill; Michelle S Kwon; Mackenzie D Martin; Amirthaa Suntharalingam; Anthony Hazel; Chad A Dickey; James C Gumbart; Raquel L Lieberman
Journal:  J Biol Chem       Date:  2019-07-02       Impact factor: 5.157

6.  Anticipation, anti-glaucoma drug treatment response and phenotype of a Chinese family with glaucoma caused by the Pro370Leu myocilin mutation.

Authors:  Chun-Mei Li; Yue-Hong Zhang; Rong-Hua Ye; Chang-Xian Yi; Yi-Min Zhong; Dan Cao; Xing Liu
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

7.  The glaucoma-associated olfactomedin domain of myocilin forms polymorphic fibrils that are constrained by partial unfolding and peptide sequence.

Authors:  Shannon E Hill; Rebecca K Donegan; Raquel L Lieberman
Journal:  J Mol Biol       Date:  2013-12-09       Impact factor: 5.469

8.  Charge Shielding Prevents Aggregation of Supercharged GFP Variants at High Protein Concentration.

Authors:  Joshua R Laber; Barton J Dear; Matheus L Martins; Devin E Jackson; Andrea DiVenere; Jimmy D Gollihar; Andrew D Ellington; Thomas M Truskett; Keith P Johnston; Jennifer A Maynard
Journal:  Mol Pharm       Date:  2017-09-18       Impact factor: 4.939

9.  Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism.

Authors:  Amirthaa Suntharalingam; Jose F Abisambra; John C O'Leary; John Koren; Bo Zhang; Myung Kuk Joe; Laura J Blair; Shannon E Hill; Umesh K Jinwal; Matthew Cockman; Adam S Duerfeldt; Stanislav Tomarev; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

10.  Mutations in the ubiquitin-binding domain of OPTN/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism.

Authors:  Wen-Chuan Shen; Huei-Ying Li; Guang-Chao Chen; Yijuang Chern; Pang-Hsien Tu
Journal:  Autophagy       Date:  2015-04-03       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.